This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly, Verve Therapeutics receive early termination from US FTC

( July 22, 2025, 21:46 GMT | Official Statement) -- MLex Summary: Eli Lilly and Verve Therapeutics were granted early termination by the US Federal Trade Commission today, according to a securities filing. The companies agreed to their $1 billion deal on June 17 and submitted relevant US antitrust paperwork on June 25, receiving clearance just days before their waiting period would have expired.See excerpt below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login